» Articles » PMID: 15643295

Familial Mediterranean Fever (FMF) in Turkey: Results of a Nationwide Multicenter Study

Overview
Specialty General Medicine
Date 2005 Jan 12
PMID 15643295
Citations 241
Affiliations
Soon will be listed here.
Abstract

Familial Mediterranean fever (FMF) is an autosomal recessive disease that is prevalent among eastern Mediterranean populations, mainly non-Ashkenazi Jews, Armenians, Turks, and Arabs. Since a large proportion of all the FMF patients in the world live in Turkey, the Turkish FMF Study Group (FMF-TR) was founded to develop a patient registry database and analyze demographic, clinical, and genetic features. The cohort was composed of 2838 patients (mean age, 23.0 +/- 13.33 yr; range, 2-87 yr), with a male:female ratio of 1.2:1. There was a mean period of 6.9 +/- 7.65 years from disease onset to diagnosis; the period was about 2 years shorter for each decade since 1981. Ninety-four percent of patients were living in the central-western parts of the country; however, their familial origins (70% from the central-eastern and Black Sea regions) reflected not only the ongoing east to west migration, but also the historical roots of FMF in Turkey. Patients' clinical features included peritonitis (93.7%), fever (92.5%), arthritis (47.4%), pleuritis (31.2%), myalgia (39.6%), and erysipelas-like erythema (20.9%). Arthritis, arthralgia, myalgia, and erysipelas-like erythema were significantly more frequent (p < 0.001) among patients with disease onset before the age of 18 years. Genetic analysis of 1090 patients revealed that M694V was the most frequent mutation (51.4%), followed by M680I (14.4%) and V726A (8.6%). Patients with the M694V/M694V genotype were found to have an earlier age of onset and higher frequencies of arthritis and arthralgia compared with the other groups (both p < 0.001). In contrast to other reported studies, there was no correlation between amyloidosis and M694V homozygosity in this cohort. However, amyloidosis was still remarkably frequent in our patients (12.9%), and it was prevalent (27.8%) even among the 18 patients with a disease onset after age 40 years. Twenty-two patients (0.8%) had nonamyloid glomerular diseases. The high prevalence of vasculitides (0.9% for polyarteritis nodosa and 2.7% for Henoch-Schonlein purpura) and high frequency of pericarditis (1.4%) were striking findings in the cohort. Phenotype II cases (those patients with amyloidosis as the presenting or only manifestation of disease) were rare (0.3% or less). There was a high rate of a past diagnosis of acute rheumatic fever, which suggested a possible misdiagnosis in children with FMF presenting with recurrent arthritis. To our knowledge, this is the largest series of patients with FMF reported from 1 country. We describe the features of the disease in the Turkish population and show that amyloidosis is still a substantial problem.

Citing Articles

The Role of Gene Expression and Serum Adropin Levels in Patients with Familial Mediterranean Fever.

Demir Eksi D, Gulbol Duran G, Celik M, Eksi Y, Gunesacar R Int J Mol Sci. 2025; 26(5).

PMID: 40076990 PMC: 11900374. DOI: 10.3390/ijms26052371.


Increasing Importance of Genotype-Phenotype Correlations Associated with Common and Rare MEFV Gene Mutations in FMF Patients in the Last Thirty Years.

Yildirim S, Bekis Bozkurt H, Erguven M J Clin Med. 2025; 14(3).

PMID: 39941383 PMC: 11818418. DOI: 10.3390/jcm14030712.


Updates on the molecular spectrum of variants in lebanese patients with Familial Mediterranean Fever.

Feghali R, Ibrahim J, Salem N, Moussallem R, Hijazi G, Attieh C Front Genet. 2025; 15:1506656.

PMID: 39897620 PMC: 11782246. DOI: 10.3389/fgene.2024.1506656.


Familial Mediterranean fever in Romania: a case report and literature review.

Iuhas A, Marinau C, Niulas L, Futaki Z, Balmos A, Kozma K Front Pediatr. 2025; 12:1546387.

PMID: 39882210 PMC: 11774843. DOI: 10.3389/fped.2024.1546387.


Characterizing Protracted Febrile Myalgia: Fasciitis and Vasculitis of the Fascia and Muscle as Novel Histopathological Features.

Hernandez-Rodriguez J, Mestre-Trabal L, Gomez-Caverzaschi V, Araujo O, Terenas M, Robaina R J Clin Med. 2025; 13(24.

PMID: 39768554 PMC: 11727829. DOI: 10.3390/jcm13247630.